glucose-dependent insulinotropic polypeptide news

All news on glucose-dependent insulinotropic polypeptide (also known as Gastric inhibitory polypeptide and GIP): plants, production capacities, investments and involved companies.

31 August 2026

Eli Lilly: Taltz plus Zepbound sustain improved psoriatic and metabolic outcomes at 52 weeks

Combination maintained or deepened psoriasis and psoriatic arthritis responses and reduced systemic inflammation while improving metabolic measures including BMI and HbA1c at one year versus Taltz alone.
28 August 2026

Eli Lilly’s Mounjaro approved by FDA to reduce cardiovascular risk in adults with type 2 diabetes

First GIP+GLP‑1 agonist authorised to lower major adverse cardiovascular events in high‑risk adults with type 2 diabetes; SURPASS‑CVOT enrolled >13,000 with ~4‑year median follow‑up.
23 July 2026

Lilly's retatrutide shows large weight and A1C reductions in Phase 3 TRIUMPH‑2 and TRIUMPH‑3

First‑in‑class triple agonist delivered large 80‑week weight losses and meaningful A1C and cardiometabolic improvements in difficult‑to‑treat obesity populations.

Who will be producing glucose-dependent insulinotropic polypeptide in the future?

Find out with chemXplore Alpha

Learn more